6 per year post-RS. Similar results were obtained in cases with high radiographic scores

and in inhibitor patients. Pain reduction was observed in most cases. Average range of motion was maintained or increased 1 year post-RS in most joints. Extension was stable or increased in 88.2% of the knees and 86.5% of the elbows. Ankle plantarflexion was stable or increased in 90.9%, whereas dorsiflexion was maintained or increased in 87.9%. Worsening of the range of motion, when present, ranged from 14 to 17 degrees. We concluded that RS with C-Y90 represents an important resource for the treatment of chronic haemophilic synovitis, markedly reducing joint bleeding frequency and pain, irrespective of the radiographic stage and inhibitor status. “
“The most commonly performed assay for factor VIII:C worldwide for many years has been the one-stage assay. mTOR inhibitor The one-stage assay is based on the activated partial thromboplastin time (APTT) and depends selleck chemicals upon the ability of a sample containing factor VIII to correct or shorten the delayed clotting of a plasma which has a complete lack of FVIII (FVIII-deficient plasma). It should be noted however that mild haemophilia A is not excluded by the finding of a normal FVIII:C level by one-stage assay, for the reasons discussed below. Several groups have reported that a subgroup of mild haemophilia A patients have discrepancy between the activity of FVIII as determined using

different types of assay [1–3]. More than 20% of mild haemophilia A patients are associated with assay discrepancy, where a twofold difference between results obtained with different assay systems is considered as discrepant [1]. In some cases the one-stage assay result may be five times higher than the two-stage clotting or chromogenic assay [1]. The most common type of assay discrepancy is to have results of one-stage assays higher than results 上海皓元 of two-stage clotting or chromogenic assay. In more than three-fourths of such patients all assay results are reduced below the lower limit of the reference range so that a diagnosis may be reliably made irrespective of which method is employed for

analysis. However, a small proportion of patients have results by the one-stage assay which is well within the normal range with reduced levels by a two-stage clotting or chromogenic assay [3,4]. These patients have bleeding histories compatible with the lower levels obtained in a two-stage clotting or chromogenic assay. In many cases the genetic defect has been identified, so there is no doubt that these subjects do indeed have haemophilia [4,5]. In our experience about 5–10% of mild haemophilia A patients have a normal one-stage assay result. This is a prevalence similar to that described by other groups. As FVIII activity is normal in the one-stage APTT-based assay, it is not surprising that the APTT is also normal in such patients.